Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers

被引:0
|
作者
Moura, Filipe A. [1 ,2 ]
Kamanu, Frederick K. [3 ]
Wiviott, Stephen D. [3 ]
Giugliano, Robert P. [3 ]
Udler, Miriam S. [4 ,5 ,6 ,7 ,8 ]
Florez, Jose C. [4 ,5 ,6 ,7 ,8 ]
Ellinor, Patrick T. [9 ,10 ]
Sabatine, Marc S. [3 ]
Ruff, Christian T. [3 ]
Marston, Nicholas A. [3 ]
机构
[1] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA
[2] VA Connecticut Healthcare Syst, West Haven, CT USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA USA
[4] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA USA
[5] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA USA
[6] Broad Inst Harvard & MIT, Programs Metab, Cambridge, MA USA
[7] Broad Inst Harvard & MIT, Programs Med & Populat Genet, Cambridge, MA USA
[8] Harvard Med Sch, Dept Med, Boston, MA USA
[9] Broad Inst MIT & Harvard, Cardiovasc Dis Initiat, Cambridge, MA USA
[10] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA
来源
DIABETES OBESITY & METABOLISM | 2025年 / 27卷 / 03期
基金
美国国家卫生研究院;
关键词
clinical trial; genetic epidemiology; genetic risk; incident diabetes; lipid-lowering therapy; PCSK9; inhibition; risk prediction; type; 2; diabetes; CARDIOVASCULAR-DISEASE; PCSK9; VARIANTS; MORTALITY;
D O I
10.1111/dom.16123
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To evaluate the predictive value of a contemporary type 2 diabetes (T2D) polygenic score (PGS) in detecting incident diabetes across a range of diabetes risk factors. Materials and Methods: We analysed participants in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (, number NCT0176463), which compared the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab versus placebo in lowering cardiovascular outcomes in participants with stable atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg/dL (1.8 mmol/L) or higher who were receiving statin therapy. Genetic risk was characterized using a previously validated T2D PGS based on similar to 1.2 million single-nucleotide polymorphisms. PGS was analysed continuously and categorically as high (top 20% of the PGS) and low to intermediate (lower 80% of the PGS). The effect of evolocumab on incident diabetes in patients without diabetes at baseline was also assessed. HbA1c was measured at baseline and every 24 weeks thereafter, while FPG was measured at baseline, week 12, week 24 and every 24 weeks thereafter. Potential cases of incident diabetes were adjudicated centrally. Hazards ratios (HRs) for incident diabetes were adjusted for baseline characteristics and ancestry. Results: Among 9388 participants, the mean age was 63 +/- 9 years and 22.7% were women, with median HbA1c 39 mmol/mol (36 mmol/mol - 41 mmol/mol; 5.7% [5.4%-5.9%]) and mean body mass index (BMI) 28.7 +/- 5 kg/m(2). Diabetes developed in 690 participants (7.3%) during 2.3 years of median follow-up. T2D PGS predicted incident T2D (HR per 1-SD 1.22, 95% CI 1.14-1.32, p < 0.001). The rates of incident T2D in the high and low to intermediate genetic risk categories were 12.1% versus 6.8%, respectively (HR 1.43 95% CI 1.20-1.70, p < 0.001). Notably, high T2D genetic risk had greater predictive strength among individuals with lower HbA1c (P-int = 0.0499) and lower BMI (P-int = 0.004). Conclusions: The T2D polygenic score serves as an independent predictor of incident diabetes, particularly among individuals with lower distribution of traditional risk factors.
引用
收藏
页码:1287 / 1295
页数:9
相关论文
共 50 条
  • [31] Genetic Testing and Type 2 Diabetes Risk Awareness
    de Groot, Mary
    Wessel, Jennifer
    DIABETES EDUCATOR, 2014, 40 (04): : 427 - 433
  • [32] Dietary Fat and the Genetic Risk of Type 2 Diabetes
    Carrasquilla, German D.
    Jakupovic, Hermina
    Kilpelaeinen, Tuomas O.
    CURRENT DIABETES REPORTS, 2019, 19 (11)
  • [33] The Genetic Risk of Kidney Disease in Type 2 Diabetes
    Pezzolesi, Marcus G.
    Krolewski, Andrzej S.
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (01) : 91 - +
  • [34] The DETECT-2 Risk Questionnaire for Prediction of Incident Type 2 Diabetes-An Extension of the Finnish Diabetes Risk Score
    Alssema, Marjan
    Vistisen, Dorte
    Heymans, Martijn W.
    Nijpels, Giel
    Colagiuri, Stephen
    Borch-Johnsen, Knut
    Dekker, Jacqueline M.
    DIABETES, 2009, 58 : A65 - A65
  • [35] Combined effects of bisphenol A and diabetes genetic risk score on incident type 2 diabetes: A nested case-control study
    Wang, Fei
    Zhang, Ying
    Zhang, Shiyang
    Han, Xu
    Wei, Yue
    Guo, Huan
    Zhang, Xiaomin
    Yang, Handong
    Wu, Tangchun
    He, Meian
    ENVIRONMENTAL POLLUTION, 2022, 307
  • [36] Type 2 diabetes risk
    不详
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2000, 92 (05) : A15 - A15
  • [37] Diabetes and the Risk of Incident Gout
    Bruderer, Saskia G.
    Bodmer, Michael
    Jick, Susan S.
    Meier, Christoph R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 46 - 47
  • [38] Statins and risk of incident diabetes
    Mascitelli, Luca
    Pezzetta, Francesca
    Goldstein, Mark R.
    LANCET, 2010, 375 (9732): : 2140 - 2141
  • [39] External Validation of the UKPDS Risk Engine in Incident Type 2 Diabetes: A Need for New Type 2 Diabetes-Specific Risk Equations
    Bannister, Christian A.
    Poole, Chris D.
    Jenkins-Jones, Sara
    Morgan, Christopher Ll
    Elwyn, Glyn
    Spasic, Irena
    Currie, Craig J.
    DIABETES CARE, 2014, 37 (02) : 537 - 545
  • [40] Common Type 2 Diabetes Genetic Risk Variants Improve the Prediction of Gestational Diabetes
    Dziedziejko, Violetta
    Safranow, Krzysztof
    Tarnowski, Maciej
    Pawlik, Andrzej
    HORMONE AND METABOLIC RESEARCH, 2019, 51 (10) : 655 - 660